Evidence map›Paper›PMID 37192626›Full record

ArticleCell reports. Medicine2023

A living ex vivo platform for functional, personalized brain cancer diagnosis.

Breanna Mann, Xiaopei Zhang, Noah Bell, Adebimpe Adefolaju, Morrent Thang, Rajaneekar Dasari, Krishna Kanchi, Alain Valdivia, Yang Yang, Andrew Buckley and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Investigating the FLASH Effect in a Rat Brain Organotypic Model With a Novel High-Energy Electron Beam.International journal of radiation oncology, biology, physics · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2'-deoxyuridine (EdU).Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Breanna MannEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Xiaopei ZhangEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Noah BellEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Adebimpe AdefolajuEshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Morrent ThangDepartment of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rajaneekar DasariEshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Krishna KanchiDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alain ValdiviaEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yang YangDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew BuckleyEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Vivien LettryEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Carolyn QuinseyDepartment of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yasmeen RaufDepartment of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David KramDivision of Pediatric Hematology-Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Noah CassidySchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David L CorcoranDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stephen RegoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yuchao JiangDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lee M GravesDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Denise DunnDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Scott FloydDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Albert BaldwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Shawn HingtgenEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: hingtgen@email.unc.edu.
Andrew B SatterleeEshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Eshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: satterle@email.unc.edu.

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platformU01TR003715 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY, FLORES, CATHERINE T · 2021 to 2024
$4.6M
Statistical Methods for Bulk-Tissue and Single-Cell Multi-Omics IntegrationR35GM138342 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yuchao Jiang · 2020 to 2026
$2.3M
NCATS NIH HHS U01 TR003715NIEHS NIH HHS P30 ES010126NIGMS NIH HHS R35 GM138342
6 · The paper itself

Abstract

Functional precision medicine platforms are emerging as promising strategies to improve pre-clinical drug testing and guide clinical decisions. We have developed an organotypic brain slice culture (OBSC)-based platform and multi-parametric algorithm that enable rapid engraftment, treatment, and analysis of uncultured patient brain tumor tissue and patient-derived cell lines. The platform has supported engraftment of every patient tumor tested to this point: high- and low-grade adult and pediatric tumor tissue rapidly establishes on OBSCs among endogenous astrocytes and microglia while maintaining the tumor's original DNA profile. Our algorithm calculates dose-response relationships of both tumor kill and OBSC toxicity, generating summarized drug sensitivity scores on the basis of therapeutic window and allowing us to normalize response profiles across a panel of U.S. Food and Drug Administration (FDA)-approved and exploratory agents. Summarized patient tumor scores after OBSC treatment show positive associations to clinical outcomes, suggesting that the OBSC platform can provide rapid, accurate, functional testing to ultimately guide patient care.

Indexed as

Brain NeoplasmsBrainChildHumansalgorithmbrain cancerbrain slicedrug screeningex vivofunctional precision medicinepatient tumorpediatricpersonalized therapiestranslational

Identifiers

PMID37192626
PMCPMC10313921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.